Hypertension Resistant To Conventional Therapy Clinical Trial
Official title:
Carotid Baroreflex Activation and Its Effect on the Chemoreflex Study
Carotid baroreflex activation therapy (BAT) by the Rheos® system produces a sustained fall in blood pressure in patients with resistant hypertension. Since the activation electrodes are implanted at the level of the carotid sinus, it is conceivable that the nearby located carotid body chemoreceptors are stimulated as well. Physiological stimulation of carotid chemoreceptors not only raises respiration, but it also increases sympathetic activity which may in part counteract the effects of BAT. The aim of the present study is to investigate whether there is evidence for concomitant carotid chemoreflex activation during BAT. We hypothesized that there is no clinically relevant co-activation of the carotid body chemoreceptors during BAT in patients with resistant hypertension.
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02539810 -
Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)
|
Phase 4 | |
Completed |
NCT02832973 -
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
|
Phase 4 | |
Completed |
NCT02282033 -
Safety and Performance Study of the Moderato System
|
N/A | |
Completed |
NCT01173029 -
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
|
N/A | |
Active, not recruiting |
NCT02837445 -
Moderato System: A Double-Blind Randomized Trial Ver 1.1
|
N/A | |
Terminated |
NCT02653222 -
Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension
|
Phase 2 | |
Recruiting |
NCT02690909 -
A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension
|
N/A |